FULL INTEGRATION OF DEEPSEEK TO ACHIEVE STRATEGIC UPGRADE OF “AI + INTELLIGENT VACCINE ENTERPRISE”
As a leading vaccine enterprise in China,
the Group actively responds to the national “AI +” industrial development
strategy, fully deploys and integrates DeepSeek, and promotes the application
of the DeepSeek R1 version in all business scenarios of the Group through a
localization strategy. This aims to achieve “cost reduction, quality
improvement and efficiency enhancement” throughout the entire lifecycle of
vaccines.
To build an intelligent vaccine research
and development system, the Group will leverage DeepSeek to obtain
higher-quality vaccine candidates through the processes of discovery, design
and manufacturing. By integrating multi-source heterogeneous data from various
biological information databases and combing pre-trained protein language
models with graph neural network architecture, we expect to achieve intelligent
screening of antigen targets and dynamic analysis of conserved regions.
Meanwhile, by connecting to real-time mutation monitoring data streams and
utilizing long and short-term memory networks, the Group can predict the future
direction of pathogen mutation, dynamically analyze conserved regions, and
predict broad-spectrum antigenic epitopes. The Group will also leverage
DeepSeek to combine generative models with deep learning techniques to optimize
mRNA vaccine sequence design and stability. By predicting the secondary
structure of mRNA, the Group can intelligently design efficient combinations of
components based on the gene expression codon preference characteristics of the
host cells to improve the mRNA stability and translation efficiency and
generate optimal sequences. In addition, the Group is exploring the use of
DeepSeek’s AI framework to optimize process parameters to enhance antigen yield
and quality.
In the clinical aspect of the Group, we
fully implement the integration of the DeepSeek R1 version with the clinical
trial management system, EDC (Electronic Data Capture) system, central
randomization system, pharmacovigilance system and laboratory management
system, driving the entire vaccine clinical trial process from data collection,
analysis to decision making to achieve intelligence, shortening the cycle of
clinical trials, while enhancing data accuracy and compliance. This enables the
researchers to focus more on core areas such as clinical project promotion,
quality assessment, ethical judgment and humanistic care, providing technical
support for the rapid marketing of vaccines. In addition to cost reduction, the
efficiency and quality of clinical research can be greatly improved.
In terms of the Group’s production and
quality management, we fully implement the integration of the DeepSeek R1
version with the MES, LIMS, and SCADA systems, to facilitate deep learning of
production, inspection data, and real-time monitoring data, and build
predictive models for production and quality inspection management, with a view
to optimizing production processes, enhancing efficiency, reducing production
cycles, and lowering energy consumption. By leveraging AI to analyze production
and inspection-related quality data, we can identify potential risks and
achieve preventive quality control. This ensures that each batch of vaccines
meets high compliance standards, further improving the stability, reliability,
and consistency of vaccine quality.
In terms of the Group’s marketing
management, we fully deploy a comprehensive integration of the DeepSeek R1
version with the CRM system to further enhance the efficiency of data analysis
and explore the value of data, and to provide data and decision-making support
for the Company’s operational management and strategic development. Based on
the historical sales data and market demand trends, we utilize AI models to
enable flexible analysis and accurate forecasting of market data. In addition,
we fully integrate the DeepSeek R1 version in aspects such as corporate
management, talent training and financial management, so as to build
enterprise-level knowledge bases, further improving the Company’s management
standards.
The Group fully integrates the DeepSeek,
and deeply penetrates AI technology into the entire industry chain, covering
research and development, production, sales, and management, so as to provide
AIM solutions for global immune prevention and control.